S 204
115th Congress
Senate
Health
Civil actions and liability
Drug safety, medical device, and laboratory regulation
Drug therapy
Health technology, devices, supplies
Long-term, rehabilitative, and terminal care
Prescription drugs
Product safety and quality
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Everywhere this bill has been
25 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 30, 2018
Became Public Law No: 115-176.
May 30, 2018
Signed by President.
May 24, 2018
Presented to President.
May 22, 2018
Motion to reconsider laid on the table Agreed to without objection.
May 22, 2018
On passage Passed by recorded vote: 250 - 169 (Roll no. 214). (text: CR H4355-4356)
May 22, 2018
Passed/agreed to in House: On passage Passed by recorded vote: 250 - 169 (Roll no. 214).(text: CR H4355-4356)
May 22, 2018
On motion to recommit with instructions Failed by the Yeas and Nays: 187 - 231 (Roll no. 213).
May 22, 2018
The previous question on the motion to recommit with instructions was ordered without objection.
May 22, 2018
DEBATE - The House proceeded with 10 minutes of debate on the motion to recommit with instructions. The instructions contained in the motion seek to require the bill to be reported back to the House with an amendment to strike everything after section 1 and insert a completely new text.
May 22, 2018
Ms. Schakowsky moved to recommit with instructions to the Committee on Energy and Commerce. (CR H4363)
May 22, 2018
The previous question was ordered pursuant to the rule.
May 22, 2018
DEBATE - The House proceeded with one hour of debate on S. 204.
May 22, 2018
Rule provides for consideration of H.R. 5515, S. 204 and S. 2155. The resolution provides for one hour of general debate on H.R. 5515, S. 204 and S. 2155. The resolution provides for consideration of S. 2155 and S. 204 under a closed rule. Also, the resolution provides for consideration of H.R. 5515 under a structured rule and makes an amendment in the nature of a substitute consisting of the text of Rules Committee Print 115-70 considered as adopted.
May 22, 2018
Considered under the provisions of rule H. Res. 905. (consideration: CR H4355-4366)
May 21, 2018
Rules Committee Resolution H. Res. 905 Reported to House. Rule provides for consideration of H.R. 5515, S. 204 and S. 2155. The resolution provides for one hour of general debate on H.R. 5515, S. 204 and S. 2155. The resolution provides for consideration of S. 2155 and S. 204 under a closed rule. Also, the resolution provides for consideration of H.R. 5515 under a structured rule and makes an amendment in the nature of a substitute consisting of the text of Rules Committee Print 115-70 considered as adopted.
Aug 11, 2017
Referred to the Subcommittee on Health.
Aug 4, 2017
Referred to the House Committee on Energy and Commerce.
Aug 4, 2017
Received in the House.
Aug 3, 2017
Message on Senate action sent to the House.
Aug 3, 2017
Passed Senate with an amendment by Unanimous Consent.
Aug 3, 2017
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Aug 3, 2017
Measure laid before Senate by unanimous consent. (consideration: CR S4788-4789)
Aug 3, 2017
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
Jan 24, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Jan 24, 2017
Introduced in Senate
Votes taken on this bill
2
| Date | Chamber | What was voted on | Result | Yes–No | |
|---|---|---|---|---|---|
| May 22, 2018 | House · vote #214 | On Passage | Passed | 250–169 | See who voted → |
| May 22, 2018 | House · vote #213 | On Motion to Recommit with Instructions | Failed | 187–231 | See who voted → |
Plain-English summary
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must report annually to the Food and Drug Administration (FDA) on any use of the drug in accordance with these provisions. The FDA shall post an annual summary report of such use on its website.
The bill limits the liability of a sponsor, manufacturer, prescriber, or dispenser that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.
What's happening now
Became Public Law No: 115-176.
Committees of jurisdiction
3